Month: September 2021

STAT+: Biden administration favors insurers over doctors in controversial new surprise billing regulations

WASHINGTON — The Biden administration on Thursday sided with insurers over physicians and other health care providers, choosing the approach they prefer for resolving disputes over surprise medical bills. Congress last year passed a landmark law to protect patients from getting large, unexpected bills in emergencies and non-emergency situations where patients can’t choose their doctors. […]

Listen: Health equity ‘tourism,’ an $11B biopharma acquisition, & a bony Covid protest

An $11 billion biopharma acquisition. Health equity “tourism.” And, where can you buy a 12-foot pyramid of bones? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we welcome STAT reporter Usha Lee McFarling onto the podcast to discuss her investigation into health equity tourism — how white […]

STAT+: Appeals court rules FDA ‘arbitrarily and capriciously’ approved a rare disease drug

In a closely watched battle over regulatory decision-making, a federal appeals court ruled the U.S. Food and Drug Administration wrongly approved a rare disease medicine made by a small, family-run company because another drug maker already held the exclusive right to market a similar treatment. The lawsuit was filed by Catalyst Pharmaceuticals (CPRX), which accused […]

STAT+: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

WASHINGTON — A key Senate panel is seriously considering a new policy that would soften the blow of drug pricing reform for small biotech companies, according to two sources familiar with the talks. But the concession isn’t likely to win over the biotech industry. The change would be part of a package of broader drug […]

STAT+: Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer

Scientists have unveiled new maps of the protein networks underlying different types of cancer, offering a potentially clearer way to see what’s driving the disease and to find therapeutic targets. Sequencing the genetic information of tumors can provide a trove of data about the mutations contained in those cancer cells. Some of those mutations help […]

STAT+: With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant

Merck will continue to search out more acquisitions after its $11 billion purchase of biotech firm Acceleron Pharma, the company’s CEO told STAT in an interview Thursday. But the CEO, Rob Davis, said he also believes that investors have not yet come to realize the value of the experimental drugs Merck is developing. Continue to […]

STAT+: Pharmalittle: House panel OKs bills to halt pharma practices that raise prices; Merck to buy Acceleron for $11.5 billion

Rise and shine, everyone, another busy day is on the way. This morning is getting off to a fabulous start, though, as a delightfully warm sun is enveloping the subdued Pharmalot campus, where the official mascot is snoozing and the leaves are ever so slowly starting to drop off the towering pin oaks outside. As […]

Telehealth has rapidly expanded. But companies are still struggling to reach rural populations

Despite the wide-ranging expansion of telehealth in the past year, there is still a broad swath of the U.S. population it has largely failed to reach: the 57 million people in rural parts of the country. Even now, as employers rush to add virtual care to their benefits, many telehealth companies have avoided rural areas. […]

Scroll to top